Clinical Trials Logo

Castleman Disease clinical trials

View clinical trials related to Castleman Disease.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04838860 Terminated - Clinical trials for Idiopathic Multicentric Castleman's Disease

Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

SISREMCAD
Start date: March 31, 2021
Phase: Phase 2
Study type: Interventional

Phase 2 study to investigate the safety, tolerability, and efficacy of administering increased siltuximab doses to patients with iMCD

NCT ID: NCT03864419 Terminated - Clinical trials for Diffuse Large B-Cell Lymphoma

Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda

Start date: October 24, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies how well rituximab hyaluronidase and combination chemotherapy work in treating patients in Uganda with Burkitt lymphoma, diffuse large B-cell lymphoma, or Kaposi sarcoma herpesvirus associated multicentric Castleman disease. Rituximab hyaluronidase is a combination of rituximab and hyaluronidase. Rituximab binds to a molecule called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Hyaluronidase allows rituximab to be given by injection under the skin. Giving rituximab and hyaluronidase by injection under the skin is faster than giving rituximab alone by infusion into the blood. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, methotrexate, etoposide, doxorubicin, and prednisone work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. While rituximab has a clear survival benefit in patients within developed countries, differences in supportive care and infectious co-morbidities require special attention. Giving rituximab hyaluronidase alone or in combination with chemotherapy may work better in treating patients with Burkitt lymphoma, diffuse large B-cell lymphoma, or Kaposi sarcoma herpesvirus associated multicentric Castleman disease compared to chemotherapy alone in Uganda.

NCT ID: NCT02080416 Terminated - Gastric Cancer Clinical Trials

Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors

Start date: July 2014
Phase: Phase 0
Study type: Interventional

The goals of this study is to determine if nelfinavir can target Epstein-Barr virus (EBV) and Kaposi sarcoma-associated herpesvirus (KSHV) in patients with certain cancers.